Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Int J Infect Dis ; 143: 107021, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38561040

RESUMEN

OBJECTIVES: Evaluate and compare the efficacy and safety of molnupiravir and favipiravir in outpatients with mild to moderate COVID-19 and at risk of severe COVID-19. METHODS: In an open-label, parallel-group, multicenter trial in Thailand, participants with moderate COVID-19 and at least one factor associated with severe COVID-19 were randomly assigned 1:1 to receive oral molnupiravir or oral favipiravir (standard of care). Phone calls for remote symptom assessment were made on Days 6, 15, and 29. Participants with worsening symptoms were instructed to return to the hospital. The primary endpoint was pulmonary involvement by Day 29, as evidenced by ≥2 of the following: dyspnea, oxygen saturation <92% or imaging. RESULTS: Nine hundred seventy-seven participants (487 molnupiravir, 490 favipiravir) were enrolled from 8 July 2022 to 19 January 2023. 98% had received ≥1 dose of COVID-19 vaccine and 83% ≥3 doses. By Day 29, pulmonary involvement occurred in 0% (0/483) in molnupiravir arm versus 1% (5/482) in favipiravir arm (-1.0%; Newcombe 95.2% CI: -2.4% to -0.0%; P = 0.021); all-cause death in 0% (0/483) and <1% (1/482); COVID-19 related hospitalization in <1% (1/483) and 1% (3/482); treatment-related adverse event in 1% (5/483) and 1% (4/486); and serious adverse event in 1% (4/483) and 1% (4/486). CONCLUSIONS: Favipiravir and molnupiravir had a similar efficacy and safety profile. Whether either of the two reduced the risk of complications during the omicron era in this population with a low risk of pulmonary involvement and a high vaccine coverage remains unclear. There were no differences in any of the safety endpoints. THAI CLINICAL TRIALS REGISTRY ID: TCTR20230111009.


Asunto(s)
Amidas , Antivirales , Tratamiento Farmacológico de COVID-19 , Citidina/análogos & derivados , Pirazinas , SARS-CoV-2 , Humanos , Amidas/uso terapéutico , Masculino , Pirazinas/uso terapéutico , Pirazinas/efectos adversos , Pirazinas/administración & dosificación , Femenino , Tailandia , Antivirales/uso terapéutico , Antivirales/efectos adversos , Antivirales/administración & dosificación , Persona de Mediana Edad , Adulto , Citidina/uso terapéutico , Citidina/efectos adversos , Citidina/administración & dosificación , Hidroxilaminas/uso terapéutico , Hidroxilaminas/efectos adversos , Hidroxilaminas/administración & dosificación , Anciano , Resultado del Tratamiento , COVID-19 , Pacientes Ambulatorios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA